Krishna Institute of Medical Sciences Q1 FY26: Revenue up 35%

Key takeaway from the Q1FY26 update

Krishna Institute of Medical Sciences Limited (KIMS) reported a strong start to FY26, with consolidated revenue from operations rising 35% year-on-year to ₹11,795 million for the quarter ended June 30, 2026. The earnings update also showed a mixed profit picture across reporting lines. Standalone net profit increased 1% quarter-on-quarter (QoQ) to ₹665 million. But consolidated net profit attributable to owners slipped to ₹415 million from ₹425 million in the previous quarter, with the disclosure indicating the impact of non-controlling interest.

The results were approved by the Board on August 3, 2026. The financials underwent a limited review by statutory auditors S.R. Batliboi & Associates LLP. Alongside earnings, KIMS also disclosed a series of corporate actions and approvals, including fundraising and financing decisions.

What KIMS reported for the quarter ended June 30, 2026

The headline number in the release was consolidated revenue from operations at ₹11,795 million, representing 35% YoY growth. On profitability, the standalone number showed stability with a marginal QoQ increase, while consolidated profit attributable to owners declined slightly versus the preceding quarter.

This divergence between standalone and consolidated profit in the quarter is important because KIMS operates through entities where non-controlling interest can influence the attributable profit line. As presented, consolidated net profit attributable to owners fell by ₹10 million sequentially, from ₹425 million to ₹415 million.

The board approval date is also relevant for market participants because it anchors the timing of disclosures and investor communications. KIMS indicated that the board meeting was scheduled for August 3, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

Board approvals: lending facility and O&M arrangement

Apart from quarterly results, the board approved a lending facility of ₹650 crore, which translates to ₹6,500 million. Such facilities typically support expansion plans, working capital needs, or refinancing, though the disclosure here only stated the approval of the facility.

The board also approved a draft operations and maintenance (O&M) deal with Golden Lan Solutions. The update did not provide financial terms for the O&M arrangement, but its inclusion alongside financing decisions suggests it is a material operating item for the company’s wider hospital and facility network.

Fundraising: QIP completed during the quarter

During the quarter, KIMS completed a Qualified Institutions Placement (QIP). The company issued 19,867,549 equity shares at ₹755 per share. The stated amount raised through the QIP was ₹15,000 million.

This transaction is a key capital markets event because it increases the equity base and brings institutional capital into the company. The pricing detail and share count provide clarity on execution, and the gross proceeds figure gives investors a reference point for potential balance sheet strengthening.

Convertible warrants: shareholder approval on July 9, 2026

KIMS also disclosed that shareholders approved on July 9, 2026 the issuance of up to 7,702,182 convertible warrants. The warrants were priced at ₹779 per warrant, aggregating up to ₹6,000 million. The disclosure stated that the issuance was to promoters and promoter group entities.

Together with the QIP, the warrants approval adds another layer to the capital plan communicated in the period. The update did not specify the timeline for conversion or other detailed terms, but it clearly quantified the potential fundraise and the proposed allottee category.

Investor communication: conference call details

KIMS scheduled a conference call for August 4, 2026 at 10:00 AM IST. The call was stated to be hosted by IIFL Capital. For investors, this is typically the primary forum to hear management commentary on operating performance, quarterly drivers, and the use of funds from recent capital actions.

The company’s results approval on August 3, 2026 and the call on August 4, 2026 set a tight disclosure-to-dialogue timeline, which is standard for listed companies reporting quarterly earnings.

Share price and on-screen market snapshot

The market snapshot included multiple price points. One cited close was ₹824.25, with a change of -₹26.40 (-3.10%). The disclosure also listed a CMP of ₹798.0. Another intraday reference point shown was “Today: 788.15”.

Because these figures were presented as snapshots, they should be read as point-in-time references around the results flow rather than a single definitive closing price for the day. Still, the presence of a -3.10% move indicates the stock was trading lower in at least one captured view.

Quick comparison items shown alongside results

The update also carried quick comparison fields for the prior quarter. It listed previous quarter revenue as ₹1,084 crore, which translates to ₹10,840 million. It also listed previous quarter PAT as ₹33 crore, or ₹330 million, and a previous quarter EBITDA margin of 19.9%.

These fields provide context for how the market-facing dashboard is framing sequential performance. However, the release’s main revenue headline for the June 2026 quarter was the consolidated revenue from operations of ₹11,795 million with 35% YoY growth.

Summary table: key disclosed numbers (normalized to ₹ million)

Capital actions table: QIP, warrants, and lending facility

Why the update matters for investors

This quarter’s disclosure combines operating performance with multiple balance sheet actions. A 35% YoY rise in consolidated revenue from operations sets the tone for FY26, while the small sequential dip in consolidated profit attributable to owners highlights how group structure and non-controlling interest can affect the final profit line.

Equally, the QIP completion and proposed warrants issuance quantify the company’s access to equity capital and promoter-linked instruments. The approved lending facility adds a debt or credit lever, which investors typically track alongside equity raises to understand the overall funding mix.

Conclusion

KIMS reported Q1FY26 consolidated revenue from operations of ₹11,795 million, up 35% YoY, with standalone net profit at ₹665 million and consolidated profit attributable to owners at ₹415 million. The board approvals on August 3, 2026 also covered a ₹6,500 million lending facility and a draft O&M deal with Golden Lan Solutions, while the quarter included a ₹15,000 million QIP. The next key event on the calendar is the investor conference call scheduled for August 4, 2026 at 10:00 AM IST with IIFL Capital.